Also listed on Edgewise Therapeutics, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Nov 6, 2039 · Low confidence
20-year base term ends Nov 6, 2039
Nov 6, 2019
Nov 6, 2039
Jun 18, 2024
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 0 of 3 maintenance fees are paid so far. Confidence: Low. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 6, 2019, when application PCT/US2019/060157, the earliest non-provisional in its chain, was filed (this one was filed Jun 11, 2021); a parent in its chain could not be resolved (the next row) | Nov 6, 2039 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 11,091,464) | resolves to Nov 6, 2039, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: PCTUS2019060157, PCTUS2019060157 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | Nov 6, 2039 | Low confidence |
This family
| Application PCT/US2019/060157 | PCT application no patent term | no patent term |
| US 11,091,464 | In force Nov 2039 | Nov 2039 |
| US 12,012,395 | this patent Nov 2039 | Nov 2039 |
| US 12,240,831 | In force Nov 2039 | Nov 2039 |
| Application 18/981,327 | Pending not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 25, 2022 Reel 60609, frame 99 | Charles River Discovery Research Services UK Limited | Edgewise Therapeutics, Inc. | Assignment of Assignor's Interest |
| Jul 25, 2022 Reel 60609, frame 110 | Winship, Paul; Steele, Chris | Charles River Discovery Research Services UK Limited | Assignment of Assignor's Interest |
| Jul 25, 2022 Reel 60609, frame 125 | Hunt, Kevin; Koch, Kevin; Russell, Alan; Schlachter, Stephen | Edgewise Therapeutics, Inc. | Assignment of Assignor's Interest |
| Aug 12, 2026 Reel 75705, frame 275 | Edgewise Therapeutics, Inc. | Servier Pharmaceuticals LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 11,091,464, ends no earlier than this term, so it caps nothing.